Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Friday, March 27, 2015, 50 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $952.94 to $10,800,000,000.00.

Highlighted Stocks Traded by Insiders:

KCG Holdings (KCG) - FREE Research Report

Daniel V. Tierney 2011 Trust, who is 10% Owner at KCG Holdings, sold 38,906 shares at $12.48 on March 27, 2015. Following this transaction, the 10% Owner owned 8.7 million shares meaning that the stake was reduced by 0.44% with the 38,906-share transaction.

The shares most recently traded at $12.43, down $0.05, or 0.42% since the insider transaction.

The average volume for KCG Holdings has been 310,200 shares per day over the past 30 days. KCG Holdings has a market cap of $1.5 billion and is part of the financial sector and financial services industry. Shares are up 6.78% year-to-date as of the close of trading on Friday.

KCG Holdings, Inc., an independent securities firm, provides various services designed to address trading needs across asset classes, product types, and time zones. The company operates through three segments: Market Making, Global Execution Services, and Corporate and Other. The company has a P/E ratio of 23.1. Currently, there are 2 analysts who rate KCG Holdings a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on KCG - FREE

TheStreet Quant Ratings rates KCG Holdings as a sell. Among the areas we feel are negative, one of the most important has been poor profit margins. Get the full KCG Holdings Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Rouse Properties (RSE) - FREE Research Report

Schall Benjamin, who is Chief Operating Officer at Rouse Properties, sold 8,871 shares at $19.32 on March 27, 2015. Following this transaction, the Chief Operating Officer owned 144,873 shares meaning that the stake was reduced by 5.77% with the 8,871-share transaction.

The shares most recently traded at $19.03, down $0.29, or 1.52% since the insider transaction. Historical insider transactions for Rouse Properties go as follows:

  • 4-Week # shares bought: 19,750
  • 4-Week # shares sold: 765
  • 12-Week # shares bought: 19,750
  • 12-Week # shares sold: 765
  • 24-Week # shares bought: 24,750
  • 24-Week # shares sold: 765

The average volume for Rouse Properties has been 264,200 shares per day over the past 30 days. Rouse Properties has a market cap of $1.1 billion and is part of the financial sector and real estate industry. Shares are up 3.13% year-to-date as of the close of trading on Friday.

Rouse Properties, Inc. owns and manages regional malls in the United States. Its portfolio consists of 30 regional malls in 19 states totaling approximately 21 million square feet of retail and ancillary space. The company is based in New York, New York. Rouse Properties, Inc. The stock currently has a dividend yield of 3.74%. Currently, there are 2 analysts who rate Rouse Properties a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on RSE - FREE

TheStreet Quant Ratings rates Rouse Properties as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity and poor profit margins. Get the full Rouse Properties Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Jazz Pharmaceuticals (JAZZ) - FREE Research Report

Mulligan Seamus, who is Director at Jazz Pharmaceuticals, sold 50,000 shares at $174.59 on March 27, 2015. Following this transaction, the Director owned 1.2 million shares meaning that the stake was reduced by 4.14% with the 50,000-share transaction.

The shares most recently traded at $174.19, down $0.40, or 0.23% since the insider transaction. Historical insider transactions for Jazz Pharmaceuticals go as follows:

  • 4-Week # shares sold: 55,500
  • 12-Week # shares sold: 65,500
  • 24-Week # shares sold: 143,312

The average volume for Jazz Pharmaceuticals has been 672,500 shares per day over the past 30 days. Jazz Pharmaceuticals has a market cap of $10.5 billion and is part of the health care sector and drugs industry. Shares are up 7.14% year-to-date as of the close of trading on Friday.

Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a P/E ratio of 186.4. Currently, there are 11 analysts who rate Jazz Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on JAZZ - FREE

TheStreet Quant Ratings rates Jazz Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, good cash flow from operations and increase in net income. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Jazz Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

null